FLINT, Mich., Feb. 16, 2016 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is now filling prescriptions for ZEPATIER™ (elbasvir and grazoprevir), with or without ribavirin, to treat adult patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 4 infection.
To learn more about Diplomat's hepatitis program, click here.
Hepatitis C is a viral disease that causes inflammation of the liver, which can lead to diminished liver function or liver failure. Some individuals with chronic hepatitis C infection may develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly. According to the Centers for Disease Control and Prevention, approximately 3.5 million Americans are infected with HCV, of which genotype 1 is the most common and genotype 4 is one of the least common.
It is estimated that less than one in five patients with chronic HCV infection are currently treated, with thousands of new cases each week. Unlike many other serious or chronic diseases, hepatitis C can be cured.
"We are excited to offer a therapy for patients with hepatitis C virus infection," said Gary Kadlec, Diplomat president. "Offering a highly effective option for a broad range of adult patients with chronic HCV genotype 1 or genotype 4 infection is a step forward in assisting our patients who otherwise would not receive treatment."
ZEPATIER™ is distributed by Merck. Click here for complete ZEPATIER™ prescribing information.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education, and Human Resources
810.768.9863 | firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-zepatier-to-treat-patients-with-chronic-hepatitis-c-virus-300220853.html
SOURCE Diplomat Pharmacy, Inc.